Doxylamine/pyridoxine (Cariban®). HTA ID: 23052

Assessment Status Rapid Review Complete
HTA ID 23052
Drug Doxylamine/pyridoxine
Brand Cariban®
Indication Doxylamine/pyridoxine (Cariban®) is indicated for the symptomatic treatment of nausea and vomiting during pregnancy in adults who do not respond to conservative management.
Assessment Process
Rapid review commissioned 11/08/2023
Rapid review completed 30/08/2023
Rapid review outcome A full HTA is not recommended. The NCPE recommends that doxylamine/pyridoxine (Cariban®) not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.